null

Anti-Human CD52 (Alemtuzumab) - Dylight® 488 Biosimilar (IVMB0476)

SKU:
IVMB0476
Antibody Type:
Dylight Biosimilar
Applications:
Drug Development
Pharmacokinetics
Disease Area:
Chronic Lymphocytic Leukemia
Disease Area:
Transplantation
€749

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human CD52 (Alemtuzumab) - Dylight 488
SKU:IVMB0476
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:Campath-1H
Target:CD52
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human/Rhesus Monkey/Cynomolgus Monkey
Applications:FA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen
Product Concentration:0.2 mg/ml
Excitation Laser:Blue Laser (493 nm)
Immunogen:Human lymphocytes.
Applications and Recommended Usage:FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted.
Formulation:This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only.
Additional Applications Reported In Literature:IHC FFPE (Formalin-fixed paraffin-embedded tissue)IHC FF (Fresh Frozen)FA
Additional Reported Applications For Relevant Conjugates:CyTOFWB

Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products